Correlation Between Cns Pharmaceuticals and ZyVersa Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Cns Pharmaceuticals and ZyVersa Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cns Pharmaceuticals and ZyVersa Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Cns Pharmaceuticals and ZyVersa Therapeutics, you can compare the effects of market volatilities on Cns Pharmaceuticals and ZyVersa Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cns Pharmaceuticals with a short position of ZyVersa Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cns Pharmaceuticals and ZyVersa Therapeutics.

Diversification Opportunities for Cns Pharmaceuticals and ZyVersa Therapeutics

0.62
  Correlation Coefficient

Poor diversification

The 3 months correlation between Cns and ZyVersa is 0.62. Overlapping area represents the amount of risk that can be diversified away by holding Cns Pharmaceuticals and ZyVersa Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ZyVersa Therapeutics and Cns Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cns Pharmaceuticals are associated (or correlated) with ZyVersa Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ZyVersa Therapeutics has no effect on the direction of Cns Pharmaceuticals i.e., Cns Pharmaceuticals and ZyVersa Therapeutics go up and down completely randomly.

Pair Corralation between Cns Pharmaceuticals and ZyVersa Therapeutics

Given the investment horizon of 90 days Cns Pharmaceuticals is expected to under-perform the ZyVersa Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Cns Pharmaceuticals is 1.39 times less risky than ZyVersa Therapeutics. The stock trades about -0.02 of its potential returns per unit of risk. The ZyVersa Therapeutics is currently generating about -0.02 of returns per unit of risk over similar time horizon. If you would invest  620.00  in ZyVersa Therapeutics on February 22, 2024 and sell it today you would lose (180.00) from holding ZyVersa Therapeutics or give up 29.03% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Cns Pharmaceuticals  vs.  ZyVersa Therapeutics

 Performance 
       Timeline  
Cns Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Cns Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with latest weak performance, the Stock's basic indicators remain invariable and the latest agitation on Wall Street may also be a sign of long-running gains for the enterprise retail investors.
ZyVersa Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days ZyVersa Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Cns Pharmaceuticals and ZyVersa Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Cns Pharmaceuticals and ZyVersa Therapeutics

The main advantage of trading using opposite Cns Pharmaceuticals and ZyVersa Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cns Pharmaceuticals position performs unexpectedly, ZyVersa Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ZyVersa Therapeutics will offset losses from the drop in ZyVersa Therapeutics' long position.
The idea behind Cns Pharmaceuticals and ZyVersa Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Other Complementary Tools

Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Commodity Directory
Find actively traded commodities issued by global exchanges